encorafenib
Foundation Medicine, Pierre Fabre Laboratories to Collaborate on CDx for Lung Cancer
The companies will seek approval for Foundation Medicine's assays identifying patients for treatment with Pierre Fabre's BRAF/MEK inhibitor combination regimen.
Pierre Fabre Seeking European Approval for Braftovi-Mektovi in BRAF-Mutated NSCLC
The application is based on results from the Phase II PHAROS trial of the targeted combination in metastatic BRAF V600E-mutated non-small cell lung cancer.
Pfizer Oncology Revenues Fall 6 Percent as Firm Anticipates Seagen Acquisition
Several of Pfizer's precision oncology products including Ibrance, Xalkori, and Braftovi saw declines in Q3.
FDA Approves Pfizer's Braftovi-Mektovi Combo, Foundation Medicine Tests for BRAF-Mutant NSCLC
The BRAF and MEK inhibitors were approved alongside Foundation Medicine's liquid biopsy and solid tumor companion tests based on Phase II PHAROS trial results.
Pfizer Oncology Revenues Fall 4 Percent in Q2; Officials Highlight Encouraging Data From Trials
Executives said the firm's acquisition of Seagen and advancement of new breast cancer candidates will help refocus its efforts in oncology.